MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To judge numerous intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Main trial objectives were being To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though on the list of https://epictetusc332pcm6.blgwiki.com/user